Pharmaceutical composition, application of pharmaceutical composition in preparation of medicine for treating lymphopenia and anti-tumor medicine

The combination of thymosin α1 and recombinant human interleukin-2 can coordinate the immune system, solve the problems of lymphopenia and immune system destruction caused by chemotherapy, significantly improve the number of lymphocytes and chemotherapy effects, and have a high degree of blood tumor patients with blood Significant therapeutic effect.

CN118987177AActive Publication Date: 2024-11-22THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411136123.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-22
Estimated Expiration
2044-08-19

AI Technical Summary

Technical Problem

Existing chemotherapeutic drugs carry out non-selective attacks on the immune system during the killing of cancer cells, leading to lymphopenia and affecting the effectiveness of tumor treatment. The existing immunomodulators are not effective in patients with severely damaged hematologic tumors of the immune system.

Method used

The composition of thymic peptide α1 and recombinant human interleukin-2 is used to coordinate the regulation of the immune system, promote lymphocyte proliferation, improve immune function, and enhance the anti-tumor effect of chemotherapy drugs.

Benefits of technology

Significantly increase the number of lymphocytes in patients with hematologic tumors, relieve lymphocytopenia, enhance the effect of chemotherapy, and improve the effect of anti-tumor treatment, especially for patients with severely damaged immune systems.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987177A_ABST
    Figure CN118987177A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of biological medicine, and discloses a pharmaceutical composition, application of the pharmaceutical composition in preparation of a medicine for treating lymphopenia and an anti-tumor medicine. The pharmaceutical composition provided by the invention comprises the thymosin alpha 1 and the recombinant human interleukin-2, and the thymosin alpha 1 and the recombinant human interleukin-2 are synergistically matched, so that the pharmaceutical composition can well act on immune systems, damaged by treatment means such as cancerous cell attack, chemotherapy, cell transplantation or targeted therapy, of tumor patients; the composition can be used for regulating the expression balance of heavy related immune factors of an immune system, improving the activity of normal lymphocytes, realizing the reconstruction of the immune system to a certain extent, promoting the proliferation of lymphocytes, especially T cell subgroups, relieving or treating lymphopenia caused by chemotherapy of tumor patients, and improving the immunity of the tumor patients. In addition, the pharmaceutical composition can also synergistically enhance the treatment effect of existing chemotherapeutic drugs, promote the removal of cancerous cells, and achieve a better tumor treatment effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine, and in particular relates to a pharmaceutical composition and its application in preparing a drug for treating lymphocytopenia and an anti-tumor drug. Background Art

[0002] Chemotherapy refers to the use of chemical drugs to inhibit or kill tumor cells to achieve anti-cancer effects. It is widely used in tumor treatment. However, existing chemotherapy drugs have poor targeting. While killing cancer cells and reducing tumor load, they also non-selectively attack the body's immune system, leading to the occurrence of lymphocytopenia. Studies have shown that lymphocytopenia significantly increases the risk of patients being infected with viruses, bacteria and other pathogens, and the reduction of immune cells leads to low or incompetent immune function, which affects the effect of tumor treatment, increases tumor cell escape, and makes the growth of tumor cells out of control, prompting tumor recurrence and metastasis. Treating or alleviating lymphocytopenia that occurs during chemotherapy in tumor patients and increasing the number of lymphocytes are conducive to improving or rebuilding the patient's immune function, thereby achieving better tumor treatment effects, which is of great clinical significance. However, there is still a lack of effective intervention measures for lymphocytopenia caused by chemotherapy in clinical practice, which has great limitations. Summary of the invention

[0003] The first purpose of the present invention is to provide a new pharmaceutical composition. The pharmaceutical composition includes thymosin α1 and recombinant human interleukin-2. Through the synergistic cooperation of thymosin α1 and recombinant human interleukin-2, it can act well on the immune system of tumor patients that has been destroyed by treatment methods such as cancerous cell attack, chemotherapy, cell transplantation or targeted therapy, regulate the expression balance of immune factors related to the immune system, improve the activity of normal lymphocytes, achieve immune system reconstruction to a certain extent, promote the proliferation of lymphocytes, especially T cell subsets, and can well alleviate or treat lymphocytopenia caused by chemotherapy in tumor patients. In addition, the pharmaceutical composition can also synergistically enhance the therapeutic effect of existing chemotherapy drugs, promote the removal of cancerous cells, and achieve better therapeutic effects.

[0004] It is worth noting that the pharmaceutical composition provided by the present invention is particularly useful for patients with blood tumors whose immune system is severely damaged (the absolute number of lymphocytes is as low as 0.03×10 9 / L), has a very good therapeutic effect. After 7 days of short-term drug treatment, the number of lymphocytes and their T cell subsets in patients with blood tumors increased significantly, effectively treating or alleviating lymphocytopenia caused by cancer cell attack, chemotherapy, cell transplantation or targeted therapy in tumor patients.

[0005] The second object of the present invention is to provide the use of the above-mentioned pharmaceutical composition in the preparation of a drug for treating lymphocytopenia.

[0006] The third object of the present invention is to provide an anti-tumor drug.

[0007] Specifically, the pharmaceutical composition provided by the present invention comprises thymosin α1 and recombinant human interleukin-2.

[0008] Furthermore, the amino acid sequence of the thymosin α1 is shown in SEQ ID NO:1.

[0009] Furthermore, the amino acid sequence of the recombinant human interleukin-2 is shown in SEQ ID NO: 2 and / or SEQ ID NO: 3.

[0010] Furthermore, the amino acid sequence of the recombinant human interleukin-2 is shown in SEQ ID NO:2.

[0011] Furthermore, the addition ratio of the thymosin α1 and recombinant human interleukin-2 is (1.5-1.8) mg: (800,000-1.20) million units.

[0012] The present invention also provides the use of the above-mentioned pharmaceutical composition in preparing a drug for treating and / or alleviating lymphocytopenia.

[0013] Furthermore, the lymphocytopenia is a side effect caused by chemotherapy in patients with hematological tumors.

[0014] The anti-tumor drugs provided by the present invention include chemotherapy drugs and the above-mentioned pharmaceutical composition.

[0015] Furthermore, the anti-tumor drug is used to treat one or more diseases selected from leukemia, lymphoma and myeloma. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 This is a graph showing the experimental results of lymphocyte expansion multiples of clinical patients in group A before and after combined drug treatment with Delusen and Ridaxin provided in the embodiments of the present invention. DETAILED DESCRIPTION

[0017] The inventors of the present invention have found in their long-term clinical work that while chemotherapy and other tumor treatments kill tumor cells, they also non-selectively attack the body's immune system, leading to the occurrence of immunodeficiency diseases such as lymphocytopenia. In particular, for blood tumors originating from the immune system, chemotherapy and other tumor treatments cause deeper and wider damage to the immune system. Although the existing known immunomodulators such as CYT107, TJ107, and KGF can improve lymphocytopenia caused by pathogen infection, non-immune system primary tumors, and their treatment to a certain extent, they do not have an improvement effect on blood tumor patients whose immune systems are severely damaged, and may even cause chemotherapy to lag, affecting the treatment effect.

[0018] Based on the above problems, the inventors have creatively discovered, after extensive research and clinical practice, that the combined treatment of hematologic malignancy patients with thymosin α1 and recombinant human interleukin-2 can significantly increase the number of lymphocytes and their T cell subsets in hematologic malignancy patients, effectively improve lymphocytopenia, and at the same time, can synergistically enhance the anti-tumor effect of chemotherapy drugs to a certain extent, achieving better therapeutic effects. Based on this, the technical solution of the present invention is obtained.

[0019] The invention provides a pharmaceutical composition, which specifically comprises thymosin alpha 1 and recombinant human interleukin-2.

[0020] In the prior art, when thymosin α1 or recombinant human interleukin-2 is administered alone to patients with blood tumors according to standard dosing, it cannot effectively improve the patient's lymphocytopenia and may even cause chemotherapy delays.

[0021] In the present invention, the pharmaceutical composition can significantly improve the patient's lymphocytopenia through the synergistic combination of thymosin α1 and recombinant human interleukin-2, while cooperating with chemotherapy drugs to inhibit and kill tumor cells, and to a certain extent rebuild the severely damaged immune system, so as to ultimately achieve better anti-tumor treatment effects.

[0022] In the present invention, the thymosin alpha-1 (Tα1) is a small molecule bioactive peptide derived from the fifth component of thymosin (TF5), and the specific amino acid sequence is preferably as shown in SEQ ID NO: 1; the present invention does not impose any particular limitation on its specific source, and it can be prepared by genetic engineering technology or purchased.

[0023] In the present invention, the recombinant human interleukin-2 (rIL-2) is a recombinant protein with lymphocyte factor activity, and the specific amino acid sequence is preferably as shown in SEQ ID NO: 2 and / or SEQ ID NO: 3; the present invention does not impose any particular limitation on its specific source, and it can be prepared by genetic engineering technology or purchased.

[0024] In some specific embodiments, the amino acid sequence of the recombinant human interleukin-2 is preferably as shown in SEQ ID NO: 2. In this case, the recombinant human interleukin-2 can better cooperate with thymosin α1 to achieve a better improvement in lymphocytopenia in tumor patients.

[0025] In the present invention, the addition ratio of thymosin α1 and recombinant human interleukin-2 is preferably (1.5-1.8):(80-120) (mg: 10,000 units), such as 1.5:80 (mg: 10,000 units), 1.6:100 (mg: 10,000 units), 1.7:80 (mg: 10,000 units), 1.8:120 (mg: 10,000 units) or any value therebetween.

[0026] In the present invention, the pharmaceutical composition may further include pharmaceutically acceptable excipients, and those skilled in the art may select from the existing known excipients according to actual needs. The present invention does not impose any particular limitation on the specific components and their ratios.

[0027] Based on the effect of the above-mentioned pharmaceutical composition in treating and / or alleviating lymphocytopenia in patients, the present invention further provides the use of the above-mentioned pharmaceutical composition in preparing a drug for treating and / or alleviating lymphocytopenia.

[0028] In the present invention, the pharmaceutical composition has the effect of treating and / or alleviating lymphocytopenia for patients with blood tumors whose immune systems are severely damaged, which is not achieved by existing known immunomodulators. In other words, the pharmaceutical composition has the effect of significantly treating and / or alleviating lymphocytopenia caused by chemotherapy in patients with blood tumors.

[0029] The present invention further provides an anti-tumor drug based on the effects of the above-mentioned pharmaceutical composition in treating and / or alleviating lymphocytosis in patients with blood tumors and in synergizing with chemotherapy drugs to enhance the therapeutic effect.

[0030] In the present invention, the anti-tumor drugs include chemotherapeutic drugs and the above-mentioned pharmaceutical composition.

[0031] In the present invention, the chemotherapy drugs are a class of drugs used to kill or inhibit the growth of tumor cells. Those skilled in the art can select them according to the actual situation of the patient and based on the "Guidelines for the Clinical Application of Anti-tumor Drugs", and the present invention does not impose any special limitation on them.

[0032] In some specific embodiments, specific examples of the chemotherapy drugs include but are not limited to: one or more of imatinib, bortezomib, belintoumab, cedamide and zanubrutinib. At this time, the pharmaceutical composition cooperates with the above-mentioned chemotherapy drugs for treating blood tumor diseases such as leukemia, lymphoma, myeloma, etc., and can well synergistically enhance the therapeutic effect of the chemotherapy drugs.

[0033] Embodiments of the present invention are described in detail below, and the examples of the embodiments are intended to be used to explain the present invention, but should not be construed as limiting the present invention. In the embodiments, if specific techniques or conditions are not specified, the techniques or conditions described in the literature in this area or the product specifications are used. If the manufacturer is not specified for reagents or instruments used, they are all conventional products that can be obtained commercially.

[0034] Example

[0035] This example is used to illustrate a pharmaceutical composition and its effect of treating and / or alleviating lymphocytopenia, specifically comprising:

[0036] 1. Case selection

[0037] The cases in the clinical trial were patients with hematological malignancies in the Department of Hematology of the First Affiliated Hospital of Xiamen University. The inclusion criteria included: (1) patients diagnosed with leukemia by bone marrow puncture, lymphoma by lymph node biopsy, or multiple myeloma according to the Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma (2022 Edition); (2) patients aged 35 to 80 years; (3) patients who had completed at least one chemotherapy, hematopoietic stem cell transplantation, or targeted therapy; (4) patients with lymphocytopenia, with an absolute lymphocyte count of <0.8×10 9 / L.

[0038] 2. Method of administration

[0039] There were 107 patients in the experiment. Under the guidance of the "Guidelines for the Clinical Application of Anti-tumor Drugs", the patients were divided into Group A, Group B, Group C, Group D and Group E for group treatment. The treatment cycle was 7 days, specifically:

[0040] Group A: 27 patients were treated with combined drug therapy at a dosage of 1 million units / d of recombinant human interleukin-2 (Delusen) and 1.6 mg / d of thymosin α1 (Zidaxin) by subcutaneous injection;

[0041] Group B: 24 patients were treated with Delusan monotherapy at a dosage of 1 million units / d via subcutaneous injection;

[0042] Group C: 26 patients were treated with 1.6 mg / d of azithromycin via subcutaneous injection.

[0043] Group D: Observation group without any treatment, with 30 cases.

[0044] 3. Observation indicators

[0045] Before treatment and on the 7th day after treatment, fasting venous blood was collected from patients in the morning, and the number of lymphocytes was detected by flow cytometry, and the lymphocyte expansion multiple was calculated. The results are shown in Table 1 and Figure 1 shown.

[0046] Table 1.

[0047]

[0048] From Table 1 and Figure 1 The test results shown show that there is no significant difference in the number of lymphocytes before and after treatment in the observation group and the treatment group treated with Delusheng or Ridaxin alone. Compared with the observation group and the treatment group treated with Delusheng or Ridaxin alone, after 7 days of combined drug treatment with Delusheng and Ridaxin, the lymphocyte expansion multiples in the patients were 9.95±11.06, and the patients with lymphocyte expansion multiples of more than 5 times accounted for more than 47% of the total number of cases, which can well improve or alleviate the lymphocytopenia of blood tumor patients whose immune system is severely damaged by chemotherapy; and in the process of combined drug treatment, only 2 patients had transient fever, and no obvious toxic side effects were observed, which has high safety.

[0049] The inventors further analyzed the lymphocytes of patients with clinical cases in group A and found that the expanded lymphocyte subsets were mainly T cells, among which CD3 + The median expansion fold of T cells was 2.75 (1.45-60), and CD4 + The median expansion fold of T cell subsets was 2.36-fold (1-18.7), CD8 + The median expansion fold of T cells was 3.92-fold (1.18-60), and that of NK cells was 1.90-fold (0.37-61).

[0050] It is worth noting that the inventors also found that the clinical use of Delusen and Ridaxin also has a certain improvement and relief effect on lymphocytopenia in patients who have undergone hematopoietic stem cell transplantation or targeted therapy.

[0051] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention without departing from the principles and intent of the present invention.

[0052] The amino acid sequences involved in the present invention are shown in Table 3.

[0053] Table 3.

[0054]

[0055]

Claims

1. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises thymosin α1 and recombinant human interleukin-2.

2. The pharmaceutical composition according to claim 1, characterized in that The amino acid sequence of the thymosin α1 is shown in SEQ ID NO:

1.

3. The pharmaceutical composition according to claim 1, characterized in that The amino acid sequence of the recombinant human interleukin-2 is shown in SEQ ID NO: 2 and / or SEQ ID NO:

3.

4. The pharmaceutical composition according to claim 1, characterized in that The amino acid sequence of the recombinant human interleukin-2 is shown in SEQ ID NO:

2.

5. The pharmaceutical composition according to claim 1, characterized in that The addition ratio of the thymosin α1 and recombinant human interleukin-2 is (1.5-1.8) mg: (800,000-1.20) million units.

6. Use of the pharmaceutical composition according to any one of claims 1 to 5 in the preparation of a drug for treating and / or alleviating lymphocytopenia.

7. The use according to claim 6, characterized in that: The lymphocytopenia is a side effect caused by chemotherapy in patients with hematological tumors.

8. An anti-tumor drug, characterized in that: The anti-tumor drug includes a chemotherapy drug and the pharmaceutical composition according to any one of claims 1 to 5.

9. The anti-tumor drug according to claim 8, characterized in that: The anti-tumor drug is used to treat one or more diseases selected from leukemia, lymphoma and myeloma.

Citation Information

Patent Citations

  • Pharmaceutical compositions containing human active protein

    KR1020160134989A